Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.52 |
| ▸ | GSR | P00390 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 2/20 | 0.52 |
| ▸ | GRM6 | O15303 | 2/20 | 0.52 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7158243 | 0.90 | GSR (0.58) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL28385659 | 0.88 | GSR (0.56) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL28980806 | 0.88 | GSR (0.56) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL28296238 | 0.88 | GSR (0.56) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL27856610 | 0.85 | SLC1A1 (0.52) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL28394544 | 0.85 | SLC1A1 (0.52) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL8652131 | 0.84 | KMT2A (0.59) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL8648790 | 0.84 | KMT2A (0.59) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL28015254 | 0.84 | SLC1A1 (0.60) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL28203156 | 0.84 | SLC1A1 (0.60) | KMT2AALOX15BLMPMP22SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116916765-A | Composition for preventing, improving or treating diseases caused by protein nitrification comprising peptide having tyrosine at its end as active ingredient | 庆尚国立大学校 产学协力团 | 2023-10-20 | — | — | CN | disclosed |
| CN-115996645-A | Composition for preventing, improving or treating diseases caused by nitration of tyrosine in protein comprising tyrosine as active ingredient | 庆尚国立大学校 产学协力团 | 2023-04-21 | — | — | CN | disclosed |
| CN-108473944-A | Novel Lactobacillus having various functions and use thereof | 庆熙大学校产学协力团 | 2018-08-31 | — | — | CN | disclosed |
| US-20180002171-A1 | NANO-BIOREACTOR APPARATUS AND METHOD OF MANIPULATING EXTRACELLULAR METABOLIC SYSTEMS | AMOABEDINY GHASSEM (IR) | 2018-01-04 | — | — | US | disclosed |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| EP-1965778-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NewThera (FR) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007017768-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2007-02-15 | — | — | WO | disclosed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | KMT2A 3171/4885ALOX15 1435/4885BLM 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.